Skip to main content

Table 4 Disease status and drug use status of survival patients with IIM through using the MDAAT, HAQDI and MRS at the end of follow-up.

From: Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China

  All PM DM ADM OM JM
No. of patients (%) 156 37 80 9 24 6
MYOACT global disease activity, 10-cm VAS score = 0, n. (%) 134(85.9) 31(83.8) 69(86.3) 7(77.8) 21(87.5) 6(100.0)
MYOACT global disease activity, 10-cm VAS score > 0, n. (%) 22(14.1) 6(16.2) 11(13.8) 2(22.2) 3(12.5) 0(0.0)
MYOACT muscle disease activity, 10-cm VAS score > 0.2, n. (%) 12(7.7) 3(8.1) 6(7.5) 2(22.2) 1(4.2) 0(0.0)
MYOACT, subscale VAS score > 0.2, no (%).       
   Constitutional 13(8.3) 1(2.7) 9(11.3) 1(11.1) 2(8.3) 0(0.0)
   Cutaneous 11(7.1) 1(2.7) 6(7.5) 2(22.2) 2(8.3) 0(0.0)
   Skeletal 7(4.5) 4(10.8) 2(2.5) 0(0.0) 1(4.2) 0(0.0)
   Gastrointestinal 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
   Pulmonary 15(9.6) 6(16.2) 6(7.5) 2(22.2) 1(4.2) 0(0.0)
   Cardiac 2(1.3) 2(5.4) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Patients with HAQDI score = 0, n. (%) 130(83.3) 33(89.2) 64(80.0) 8(88.9) 17(70.8) 6(100.0)
Patients with HAQDI score > 0, n. (%) 26(16.7) 4(10.8) 15(18.8) 1(11.1) 6(25.0) 0(0.0)
Patients with M RS = 0, n. (%) 131(84.0) 34(91.9) 66(82.5) 9(100) 16(66.7) 6(100.0)
Patients with MRS ≥1, n. (%) 25(16.0) 3(8.1) 14(17.5) 0(0.0) 8(33.3) 0(0.0)
Medication       
   Off all drugs 29(18.6) 9(24.3) 16(20.0) 1(11.1) 3(12.5) 0(0.0)
   Corticosteroid, 0-5 mg/d, n. (%) 73(46.8) 16(43.2) 37(46.3) 4(44.4) 12(50.0) 4(66.7)
   Corticosteroid, 5-10 mg/d, n. (%) 34(21.8) 8(21.6) 17(21.3) 2(22.2) 5(20.8) 2(33.3)
   Corticosteroid, 10-15 mg/d, n. (%) 9(5.8) 1(2.7) 6(7.5) 0(0.0) 2(8.3) 0(0.0)
   Corticosteroid, > 15 mg/d, n. (%) 11(7.1) 3(8.1) 4(5.0) 2(22.2) 2(8.3) 0(0.0)
   Second-line agents†, n. (%) 30(19.2) 10(27.0) 14(17.5) 1(11.1) 3(12.5) 2(33.3)
  1. MYOACT, the Myositis Disease Activity Assessment Visual Analogue Scales; VAS, visual analogue scale; HAQDI, health assessment questionnaire disabled index; MRS, modified rankin scale.
  2. †second-line agents include methotrexate, cyclophosphamide, azathioprine, intravenous immunoglobulin, hydroxychloroquine or mycophenolate mofetil.